Indication
Hemostatic Disorders
1 clinical trial
1 product
Product
OriCAR-017Clinical trial
A Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Anti-GPRC5D CAR-T Cell Product (OriCAR-017) in Subjects With Relapsed/Refractory Multiple Myeloma.Status: Recruiting, Estimated PCD: 2026-12-12